List of Excipients in Branded Drug SOMA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	SOMA	carisoprodol	16590-755	ALGINIC ACID
STAT RX USA LLC	SOMA	carisoprodol	16590-755	MAGNESIUM STEARATE
STAT RX USA LLC	SOMA	carisoprodol	16590-755	POTASSIUM SORBATE
STAT RX USA LLC	SOMA	carisoprodol	16590-755	TRIBASIC CALCIUM PHOSPHATE
Ipsen Biopharmaceuticals Inc	SOMATULINE DEPOT	lanreotide acetate	15054-1060	ACETIC ACID
Ipsen Biopharmaceuticals Inc	SOMATULINE DEPOT	lanreotide acetate	15054-1060	WATER

SOMA Excipient Strategy and Commercial Opportunities for Carisoprodol Tablets

Last updated: August 4, 2026

SOMA is the branded immediate-release carisoprodol tablet, marketed historically in 250 mg and 350 mg strengths. Its commercial opportunity is no longer based on compound exclusivity. Carisoprodol was approved decades ago, generic versions are widely available, and the strongest opportunities now involve formulation differentiation, supply reliability, controlled-substance compliance, packaging, and targeted generic substitution.

The principal excipient strategy for SOMA is conventional immediate-release tablet manufacture: microcrystalline cellulose for tablet structure, corn starch and sodium starch glycolate for disintegration, povidone for binding, colloidal silicon dioxide for flow, magnesium stearate for lubrication, and pigments for product identification. A differentiated product would need to improve abuse resistance, gastrointestinal tolerability, dose flexibility, stability, or manufacturing economics without delaying release or creating new controlled-substance risks.

What is SOMA and which excipients does it contain?

SOMA contains carisoprodol, a centrally acting skeletal muscle relaxant. The approved product is an immediate-release oral tablet indicated for short-term treatment of acute, painful musculoskeletal conditions, generally for periods of up to two or three weeks depending on the applicable labeling. Carisoprodol is metabolized in part to meprobamate, a controlled substance associated with sedative and dependence risks.[1,2]

Historical SOMA labeling identifies the following inactive ingredients for the tablet formulation:

Excipient category	Representative SOMA excipients	Commercial function
Diluent and structural excipient	Microcrystalline cellulose	Tablet bulk and mechanical strength
Disintegrants	Corn starch; sodium starch glycolate	Rapid tablet breakup after ingestion
Binder	Povidone	Granule and tablet cohesion
Glidant	Colloidal silicon dioxide	Powder flow and content uniformity
Lubricant	Magnesium stearate	Ejection from the tablet press
Anti-adherent or processing aid	Talc	Manufacturing performance
Colorants	FD&C and D&C aluminum lakes	Strength and product identification

The exact excipient list can differ by strength, manufacturer, country, and product-generation version. Generic carisoprodol tablets may use different dyes, film coatings, fillers, or disintegrants while maintaining the same active ingredient and immediate-release profile. DailyMed labeling and the FDA Inactive Ingredient Database are the primary sources for product-specific composition and precedent assessment.[3,4]

What role do SOMA excipients play in product performance?

SOMA’s formulation is designed for immediate release rather than extended release or delayed release. The commercial performance targets are therefore:

• Rapid disintegration and dissolution
• Uniform delivery of carisoprodol across the tablet
• Adequate hardness for packaging and transport
• Low friability
• Consistent appearance across 250 mg and 350 mg strengths
• Stability under ordinary storage conditions
• Efficient high-volume manufacture

The formulation does not appear to depend on a novel delivery system, lipid vehicle, polymer matrix, or complex solubilization technology. That limits the scope for broad formulation exclusivity but reduces manufacturing complexity for generic applicants.

What patents protect SOMA and when does SOMA lose exclusivity?

SOMA has no meaningful remaining small-molecule exclusivity barrier based on the age of carisoprodol approval and the availability of generic products. The core active-ingredient patent position has expired, and historical product protection does not prevent generic entry.

Exclusivity category	SOMA status
New chemical entity exclusivity	Expired
Original compound patent protection	Expired
Pediatric exclusivity	No current commercial effect
Formulation exclusivity	No widely recognized barrier to generic immediate-release tablets
Method-of-use exclusivity	No current barrier apparent for the labeled short-term use
Orange Book patent protection	No commercially significant patent barrier associated with ordinary generic carisoprodol tablets
Generic availability	Established

The relevant commercial question is therefore not whether a competitor can enter the carisoprodol market. It is whether a competitor can obtain approval, maintain controlled-substance compliance, and earn acceptable margins in a mature market.

FDA ANDA applicants normally need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. A Paragraph IV certification would matter only if an unexpired Orange Book patent were listed against the reference product. For conventional SOMA tablets, the principal pathway is more likely an ANDA relying on expired protections or certifications that do not require challenging a live patent.[5]

What is the FDA regulatory status of SOMA and carisoprodol?

Carisoprodol is an FDA-approved prescription drug and a Schedule IV controlled substance in the United States. The Drug Enforcement Administration classified carisoprodol as Schedule IV because of abuse, dependence, and diversion risks.[2]

The key regulatory constraints are:

1. Prescription-only distribution.
2. Schedule IV controlled-substance registration and recordkeeping.
3. Manufacturing, inventory, security, and distribution controls.
4. Labeling that addresses sedation, impairment, abuse, dependence, withdrawal, and interaction with other central nervous system depressants.
5. Short-duration treatment positioning.
6. Bioequivalence and quality requirements for generic tablets.

The regulatory profile affects excipient selection. A manufacturer should avoid an excipient package that increases sedation-related tolerability concerns, produces variable release, or complicates dose dumping and abuse-risk analysis. A new formulation that changes release characteristics may require a 505(b)(2) application rather than a conventional ANDA, depending on the reference product and the proposed claims.[6]

How many patents cover SOMA formulations?

No broad, commercially decisive patent estate is generally associated with the conventional SOMA immediate-release tablet. Potentially relevant patents could arise from a later-developed formulation, manufacturing process, packaging system, or abuse-deterrent design, but those rights would protect the specific improvement rather than carisoprodol itself.

A realistic freedom-to-operate review should separate four patent groups:

Patent group	Relevance to a SOMA competitor
Carisoprodol composition patents	Low relevance because core rights are expired
Immediate-release tablet patents	Usually low unless a specific proprietary composition is claimed
Abuse-deterrent formulations	Potentially relevant to a differentiated product
Manufacturing or process patents	Relevant if the process is essential and still enforceable
Combination-product patents	Relevant only to products combining carisoprodol with another active ingredient
Packaging and dispensing patents	Potentially relevant for controlled-substance systems

Patent strength is likely weak for ordinary generic entry but could be moderate for a narrowly claimed abuse-deterrent formulation with strong clinical or in vitro performance data. A patent covering only a routine excipient substitution would face validity and obviousness risks, particularly where the excipient is listed in FDA-approved products or the Inactive Ingredient Database.

What formulations are protected or commercially attractive for SOMA?

Immediate-release generic tablets

The lowest-risk opportunity is a conventional 250 mg or 350 mg immediate-release tablet. The formulation can use standard excipients with established regulatory precedent. Competitive advantages would come from:

• Lower manufacturing cost
• Reliable active-pharmaceutical-ingredient supply
• Improved tablet robustness
• Fewer colorants
• Smaller tablet size
• Better packaging efficiency
• Low complaint rates
• Reliable controlled-substance distribution

This route is commercially practical but usually low margin.

Dye-free or excipient-reduced tablets

A dye-free carisoprodol tablet could target patients or prescribers concerned about color additives. Removing aluminum lakes may improve market access for certain institutional buyers, but it is unlikely to create durable exclusivity. A simpler excipient package may also reduce supplier concentration and allergen-related complaints.

The principal development risks are visual differentiation, content uniformity, tablet hardness, and patient confusion between strengths.

Orally disintegrating tablets

An orally disintegrating tablet could provide differentiation for patients with difficulty swallowing. The design would require careful control of taste, mouthfeel, dose uniformity, friability, and moisture sensitivity.

Commercial value is constrained by the drug’s controlled-substance profile. An easier-to-administer dosage form could improve convenience but could also raise diversion and misuse concerns. The product would need packaging and labeling that address those risks.

Abuse-deterrent formulations

Abuse deterrence is the most defensible high-value formulation concept. Possible approaches include:

• Polymer-based tablets that resist crushing
• Gelling systems that limit extraction
• Bitterness or aversive agents
• Physical barriers to powder formation
• Combination with antagonistic or sequestering components
• Packaging that limits rapid access

A formulation that only makes the tablet harder to crush may not qualify for an abuse-deterrent label claim. FDA’s abuse-deterrent guidance requires a meaningful body of evidence, including laboratory, pharmacokinetic, and potentially clinical studies depending on the proposed claim.[7]

The commercial opportunity is real but limited by the size and maturity of the carisoprodol market. Development costs, regulatory review, controlled-substance handling, and payer reluctance could exceed the price premium available from a standard generic.

Extended-release carisoprodol

An extended-release formulation could reduce dosing frequency and potentially reduce peak-related sedation. It would also create a new pharmacokinetic profile and require substantial clinical and regulatory work.

The main barriers are:

• Demonstrating consistent release
• Establishing bioequivalence or comparative pharmacokinetics
• Managing dose dumping
• Addressing the active meprobamate metabolite
• Supporting a new dosing regimen
• Establishing a clinical benefit over inexpensive immediate-release tablets

This is a higher-risk 505(b)(2) opportunity rather than a routine generic strategy.

What commercial opportunities exist for SOMA excipients?

How can excipients improve generic manufacturing economics?

The most immediate opportunity is cost and yield optimization. A manufacturer can evaluate:

• Direct compression versus wet granulation
• Lower-cost grades of microcrystalline cellulose
• Co-processed excipients
• Alternative superdisintegrants
• Reduced lubricant levels
• Improved powder flow
• Smaller tablet tooling
• Reduced blend segregation
• Lower moisture sensitivity

Any change must preserve dissolution, assay, content uniformity, hardness, friability, and stability. Excipients that improve processing but slow dissolution could create an ANDA equivalence problem.

Which excipient suppliers could benefit?

Opportunities exist for suppliers of:

• High-functionality microcrystalline cellulose
• Co-processed direct-compression systems
• Low-nitrite or low-impurity excipients
• Fast-acting superdisintegrants
• Taste-masking polymers
• Moisture-barrier coatings
• Tamper-evident and unit-dose packaging materials

The most attractive suppliers will offer validated pharmaceutical grades, global regulatory documentation, dual sourcing, and reliable supply for controlled-substance manufacturers.

Can a new excipient create patent protection?

A new excipient alone rarely creates strong product protection unless it produces an unexpected technical effect. More defensible claims could cover:

• A specific carisoprodol-to-excipient ratio
• A defined dissolution profile
• Abuse-deterrent mechanical properties
• Reduced impurity formation
• Improved stability under accelerated conditions
• A manufacturing process that achieves a critical performance result
• A dosage form with a demonstrated pharmacokinetic advantage

Patent drafting should link the excipient selection to measured performance. Generic claims that recite common excipients at routine concentrations are vulnerable to obviousness challenges.

What generic entry risks exist for SOMA?

The main risks are commercial and regulatory rather than patent-based.

Risk	Assessment
Patent challenge	Low for ordinary immediate-release carisoprodol
ANDA approval risk	Moderate if dissolution or content uniformity is difficult
Controlled-substance compliance	High operational importance
API supply	Potentially material in a concentrated supplier market
Price erosion	High
Product liability	Elevated because of sedation, abuse, dependence, and impaired driving risks
Recall exposure	Moderate to high if tablet-strength mix-ups occur
Abuse-deterrent development	High cost and regulatory complexity
Payer differentiation	Limited for standard tablets

A generic launch would likely follow one of three models:

1. A low-cost 350 mg tablet competing on supply and price.
2. A broader portfolio covering both strengths, with dye-free or excipient-reduced options.
3. A differentiated 505(b)(2) product using an orally disintegrating, extended-release, or abuse-deterrent design.

The first model has the lowest regulatory risk but the weakest margin. The third model has the strongest potential differentiation but requires evidence that the formulation solves a clinically relevant problem.

Which companies are challenging SOMA, and what is the competitive landscape?

The carisoprodol market is primarily a generic market. Competition comes from manufacturers holding approved ANDAs for carisoprodol tablets, distributors supplying institutional and retail channels, and branded or authorized-generic channels where available.

The principal competitive factors are:

• Wholesale acquisition price
• Product availability
• Controlled-substance distribution capacity
• FDA inspection history
• Recall record
• API sourcing
• Strength coverage
• Pharmacy substitution
• Contracting with wholesalers and group purchasing organizations

There is no biosimilar risk because carisoprodol is a chemically synthesized small molecule, not a biologic. Competitive pressure instead comes from other skeletal muscle relaxants, including cyclobenzaprine, tizanidine, methocarbamol, and baclofen. These products compete for the same prescribing occasions but differ in sedation, dosing, abuse potential, and clinical positioning.

What patent litigation and settlement agreements affect SOMA?

No major current patent-litigation barrier is generally associated with ordinary generic SOMA tablets. Because the principal patent and regulatory exclusivity periods expired long ago, Paragraph IV litigation is not the central market-entry issue.

Settlement agreements would become relevant only if a later reformulation received a patent listing or if a new branded carisoprodol product generated Orange Book-listed patents. Any such agreement would require review for:

• Entry date provisions
• Authorized-generic rights
• Supply restrictions
• Product-specific carve-outs
• Antitrust risk
• Controlled-substance distribution obligations

For current market planning, litigation exposure is materially lower than compliance, quality, pricing, and liability exposure.

How does SOMA compare with competing muscle relaxants?

Product	Active ingredient	Formulation opportunity	Abuse or dependence concern	Generic pressure
SOMA	Carisoprodol	Abuse deterrence, ODT, ER, dye-free tablet	Meaningful; Schedule IV	High
Flexeril and generics	Cyclobenzaprine	ER capsules, ODT, combination products	Sedation; not federally Schedule IV	High
Zanaflex and generics	Tizanidine	Dose optimization, oral solution	Hypotension and sedation	High
Robaxin and generics	Methocarbamol	High-dose tablet and liquid options	Sedation; lower controlled-substance burden	High
Lioresal and generics	Baclofen	Oral liquid, intrathecal delivery	Withdrawal and CNS effects	High

SOMA has a weaker patent moat than many newer specialty products. Its commercial value depends on brand recognition, prescribing familiarity, and product availability rather than exclusivity.

What is the revenue exposure and investment case?

Revenue exposure is concentrated in a mature, price-sensitive prescription market. A standard generic manufacturer should model rapid price erosion, limited brand premium, and the cost of controlled-substance infrastructure. A branded reformulation could improve revenue per prescription, but its success would depend on evidence that prescribers and payers value the new feature.

The most investable opportunities are:

1. Dual-source excipient platforms that reduce manufacturing interruptions.
2. Dye-free or low-excipient tablets for institutional purchasing.
3. Abuse-deterrent designs supported by credible testing.
4. Unit-dose packaging and dispensing controls.
5. Combination or alternate dosage forms with a clear clinical rationale.
6. Contract manufacturing for approved ANDA holders.

A conventional SOMA tablet has low patent strength but predictable manufacturing requirements. A novel formulation can create stronger protection only when the excipient system produces measurable, non-routine performance.

Key Takeaways

• SOMA is the branded carisoprodol immediate-release tablet, historically available in 250 mg and 350 mg strengths.
• Its core patent and regulatory exclusivity have expired, and generic competition is established.
• The conventional excipient system uses standard tablet ingredients, including microcrystalline cellulose, starches, povidone, colloidal silicon dioxide, magnesium stearate, talc, and colorants.
• The strongest near-term opportunity is manufacturing and supply-chain optimization, not basic composition-of-matter protection.
• Abuse-deterrent, orally disintegrating, extended-release, dye-free, and excipient-reduced formulations offer differentiated development paths.
• Controlled-substance compliance, product liability, pricing pressure, and distribution controls are more important than Paragraph IV litigation for ordinary generic entry.
• No biosimilar issue applies because carisoprodol is a small-molecule drug.
• A patentable formulation must connect the excipient choice to a measurable technical effect.

FAQs About SOMA Excipients and Commercial Strategy

Is carisoprodol still protected by patents?

The original carisoprodol patent and associated exclusivity periods have expired. Ordinary immediate-release generic tablets face no meaningful core-patent barrier.

Does SOMA contain lactose or gluten?

Historical SOMA labeling identifies starch-based and cellulose-based excipients rather than lactose. Gluten status should be determined from the current product-specific label and supplier declarations because formulations can differ by manufacturer.

Can a company launch a dye-free generic SOMA tablet?

Yes. A dye-free product could be developed as an ANDA if it meets pharmaceutical equivalence, bioequivalence, quality, labeling, and stability requirements. The change would not normally create substantial patent protection.

Would an abuse-deterrent carisoprodol tablet qualify for new exclusivity?

Potentially, but only if the product receives qualifying regulatory protection or claims supported by a novel, patentable formulation. Mechanical resistance alone does not guarantee an abuse-deterrent label claim or commercial exclusivity.

Is SOMA a good candidate for an extended-release formulation?

It is technically possible but commercially challenging. The developer would need to establish a clinically useful dosing advantage, control carisoprodol and meprobamate exposure, demonstrate reliable release, and justify the price premium over inexpensive immediate-release generics.

References

1. U.S. Food and Drug Administration. (n.d.). SOMA (carisoprodol) tablets prescribing information.
2. U.S. Drug Enforcement Administration. (n.d.). Carisoprodol.
3. National Library of Medicine. (n.d.). DailyMed: Carisoprodol tablet labeling.
4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. U.S. Food and Drug Administration. (1999). Applications covered by section 505(b)(2).
7. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling.